Login to Your Account

Safety Profile Clean

Apremilast Nails Primary Endpoint in Psoriasis Phase III

By Catherine Shaffer
Staff Writer

Monday, March 4, 2013

Celgene Corp. presented detailed results from its ESTEEM 1 Phase III trial of apremilast for psoriasis at the annual meeting of the American Academy of Dermatology in Miami. The trial met the threshold for statistical significance for its primary endpoint of 75 percent improvement in psoriasis area and severity index (PASI-75) at week 16 compared to placebo.

It assessed efficacy and safety in about 1,250 patients with moderate-to-severe chronic plaque psoriasis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription